Table 1 Peptides used in this study.
Peptide | Amino Acid Position | Sequence | MW | Maximum Solubility (μM)* |
|---|---|---|---|---|
Pcr-400 | gp21 400–429 | CCFLNITNSHVSILQERPPLENRVLTGWGL | 3,411 | > 90.00 |
Pcr-400 L/A | gp21 400–429 | ---A---------A-----A----A----A | 3,200 | 45.00 |
PBLV-391 | gp30 391–419 | CCFLRIQNDSIIRLGDLQPLSQRVSTDWQ | 3,447 | > 90.00 |
PBLV-ΔN | gp30 400–419 | S------------------- | 2,312 | > 90.00 |
PBLV-ΔC | gp30 391–410 | -------------------L | 2,317 | > 90.00 |
PBLV-L/A | gp30 391–419 | ---A---------A--A--A--------- | 3,236 | 45.00 |
PBLV-L404/410A | gp30 391–419 | -------------A-----A--------- | 3,321 | > 90.00 |
PBLV-ΔCCF | gp30 394–419 | L------------------------- | 3,052 | 11.25 |
PBLV-R403A | gp30 391–419 | ------------A---------------- | 3,321 | 22.50 |
C34 | gp41 627–661 | GWMEWDREINNYTSLLIHSLIEESQNQQEKNEQELL | 4,418 | > 90.00 |